Clinical trials, such as CheckMate 459, KEYNOTE-240, and IMbrave150, have demonstrated that a substantial proportion of HCC patients significantly benefitted from anti-PD-1 treatment [35–37], and clinical application of anti-PD-1 immunotherapy in HCC is expected to widen in the future. Here, PDCD1 is linked to hepatocellular carcinoma.